Finance
Beta
search
Search or ask
settings
Theme
mobile
Device default
✓
dark_mode
Dark theme
light_mode
Light theme
Search labs
feedback
Send feedback
Sign in
Lists
playlist_add
New
4016
Research
4016:TADAWUL
check_indeterminate_small
Middle East Pharmaceutical Inds Co SJSC
SAR 61.05
arrow_upward
+0.08%
(
+0.050
) 1D
Jul 2, 3:15:56 PM GMT+3 · SAR
area_chart
Area
stacked_line_chart
Compare
search
close
All symbols
monitoring
Indicators
No data
1D
5D
1M
6M
YTD
1Y
5Y
MAX
Symbol
Price
Change
% Change
Overview
Earnings
Financials
insights_auto
Generating top insights for 4016...
Open
SAR 61.00
High
SAR 61.30
Low
SAR 60.75
Mkt. cap
2.14B
Avg. vol.
141.99K
Volume
43.42K
Dividend
2.27%
Quarterly dividend
SAR 0.35
Ex-dividend date
Mar 30, 2026
P/E ratio
20.45
52-wk high
SAR 79.09
52-wk low
SAR 53.89
EPS
SAR 2.99
Shares outstanding
20.24M
No. of employees
731
Open
SAR 61.00
High
SAR 61.30
Low
SAR 60.75
Mkt. cap
2.14B
Avg. vol.
141.99K
Volume
43.42K
Dividend
2.27%
Quarterly dividend
SAR 0.35
Ex-dividend date
Mar 30, 2026
P/E ratio
20.45
52-wk high
SAR 79.09
52-wk low
SAR 53.89
EPS
SAR 2.99
Shares outstanding
20.24M
No. of employees
731
Related stocks
9514
Mohammed Hasan AlNaqool Sons Co SCJSC
SAR 88.20
+0.23%
arrow_upward
8010
Company for Cooperative Insurance SJSC
SAR 144.50
-1.57%
arrow_downward
4327
Al Ramz Real Estate Co
SAR 54.75
-2.23%
arrow_downward
2082
Acwa Power Company SJSC
SAR 194.30
-1.37%
arrow_downward
News stories
From sources across the web
富途牛牛
·
1 hour ago
Weekend Reading | SK Hynix Targets Nasdaq: Is the AI Era’s Ultimate 'Shovel Seller' Here?
Yardeni QuickTakes
·
13 hours ago
US MARKET CALL: A Bubble In Bubbles?
MSN
·
2 hours ago
The Dow is up 8% so far this year -- its best 6 months since 2021. Should you buy this DJIA ETF?
Yahoo Finance
·
4 hours ago
SpaceX Is Set to Join the Nasdaq-100 on July 7. Here's Where History Says the Stock Could Trade 1 Year From Now.
Show more
About Middle East Pharmaceutical Inds Co SJSC
CEO
Mohamed Maher Al Ghannam
Employees
731
Founded
1998
Headquarters
Riyadh, Riyadh Province, Saudi Arabia
Sector
Pharmaceutical industry
Website
avalonpharmaceutical.com
Previous reports
All values in SAR
Loading Previous Earnings...
Income statement
Balance sheet
Cash flow
Income statement
Revenue
Net income
calendar_month
Quarterly
Quarterly
Annual
All values in SAR
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
117.66M
107.95M
137.52M
130.13M
Cost of goods sold
44.31M
45.81M
47.32M
49.78M
Cost of revenue
44.31M
45.81M
47.32M
49.78M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
45.37M
50.78M
43.26M
48.09M
Operating expense
45.56M
51.48M
43.77M
50.05M
Total operating expenses
89.87M
97.29M
91.08M
99.83M
Operating income
27.78M
10.66M
46.43M
30.30M
Other non operating income
-
-
-
-
EBT including unusual items
27.05M
9.82M
45.93M
29.13M
EBT excluding unusual items
27.05M
9.82M
45.89M
29.13M
Income tax expense
2.24M
1.54M
1.41M
2.23M
Effective tax rate
8.29%
15.69%
3.07%
7.67%
Other operating expenses
184.76K
-147.78K
-109.44K
-54.06K
Net income
24.81M
8.28M
44.52M
26.90M
Net profit margin
21.09%
7.67%
32.38%
20.67%
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
-
Interest expense
-731.86K
-844.49K
-562.26K
-1.16M
Net interest expenses
-731.86K
-844.49K
-562.26K
-1.16M
Depreciation and amortization charges
-
-
-
-
EBITDA
30.78M
13.78M
49.70M
33.47M
Gain or loss from assets sale
-
-40.87K
-55.44K
-
AI content may include mistakes.
Learn more
Help
Send feedback
Privacy
Terms
Disclaimer
Research
edit_square
New thread
notes_spark
Thread history
close
Collapse
expand_content
Expand
What's on your mind?
What's going on with the markets today?
search_spark
Explore what’s possible
travel_explore
Deep Search
mic
Voice Search
add
Add Tool
upload_file
Upload File
travel_explore
Deep Search
arrow_upward
Ask AI
search_spark
mic
Voice Search
AI content may include mistakes.
Learn more
Help
Send feedback
Privacy
Terms
Disclaimer